1 – 10 of 31
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
(
- Contribution to journal › Article
-
Mark
The need for core outcome sets in renal cancer clinical effectiveness research
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer
(
- Contribution to journal › Scientific review
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making : Proposal from the European Association of Urology Guidelines Panel
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022 : The Urologist's Point of View
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2022 Update
(
- Contribution to journal › Scientific review
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Recurrence pattern in localized RCC : results from a European multicenter database (RECUR)
(
- Contribution to journal › Article
- 2021
-
Mark
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials
(
- Contribution to journal › Article